Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Tax Provisions: 2018-2023

Historic Tax Provisions for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Dec 2023 value amounting to -$1.8 million.

  • Lineage Cell Therapeutics' Tax Provisions was N/A to -$1.8 million in Q1 2023 from the same period last year, while for Mar 2023 it was -$16.3 million, marking a year-over-year change of. This contributed to the annual value of -$1.8 million for FY2023, which is 433.27% down from last year.
  • Lineage Cell Therapeutics' Tax Provisions amounted to -$1.8 million in FY2023, which was down 433.27% from $541,000 recorded in FY2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Tax Provisions peaked at $541,000 during FY2022, and registered a low of -$7.4 million during FY2019.
  • Over the past 2 years, Lineage Cell Therapeutics' median Tax Provisions value was -$631,000 (recorded in 2022), while the average stood at -$631,000.
  • In the last 5 years, Lineage Cell Therapeutics' Tax Provisions crashed by 2,240.75% in 2019 and then spiked by 83.27% in 2020.
  • Lineage Cell Therapeutics' Tax Provisions (Yearly) stood at -$7.4 million in 2019, then soared by 83.27% to -$1.2 million in 2020, then reached $541,000 in 2022, then crashed by 433.27% to -$1.8 million in 2023.